1800 244 735

Helpline (02) 9874 9777

Therapeutics conference videos now online

HDBuzz covered CHDI’s therapeutics conference in February 2011 from Palm Springs. Now, videos of many of the scientific presentations have been made available to watch online.

The therapeutics conference

The annual Huntington’s disease Therapeutics Conference, hosted by CHDI Foundation Inc., is a unique forum for HD researchers to come together, share exciting findings, and establish collaborations and partnerships that accelerate the pace of research into therapies for Huntington’s disease.

CHDI is a not-for-profit ‘virtual biotechnology company’ that aims to “rapidly discover and develop drugs that delay or slow Huntington’s Disease”. It’s the largest single driving force behind the development HD treatments.

Shortly after HDBuzz launched in January, we reported from the 2011 Therapeutics Conference, held in Palm Springs, California. Our daily reports from the conference gave a plain-language overview of all the main science presented at the conference – and it was a ton of exciting stuff!

You can find our reports by searching for ‘CHDI’ on HDBuzz.net.

The videos

For the first time, videos of many of the scientific presentations have now been made available online. To find them, visit http://chdifoundation.org/ and click the ‘Presentations from the 2011 HD Therapeutics Conference’ link.

Be prepared, though: these presentations were delivered by scientists, to a room full of scientists – so they’re all rather more intensive than a typical HDBuzz article!

So, you might find helpful to consult our daily conference reports, alongside the videos.

We applaud this move – it was an exciting conference and the science deserves to reach as many people as possible. As far as HDBuzz is concerned, making conference presentations available online like this is a great step forward.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Meeting 2021

Published date: 28 October, 2021

Last month, the Huntington’s disease (HD) research community, patients and other stakeholders met online at the European Huntington’s disease network (EHDN) conference. Despite the ongoing global pandemic, there is a tremendous amount of work underway in labs and clinics around the world as researchers continue to better understand HD and how we might best treat ... Read more

Real talk: Q&A with Roche about GENERATION-HD1

Published date: 28 September, 2021

At the end of day 1 of the European Huntington’s Disease Network (EHDN) conference, the HDBuzz team (minus one) sat down for a zoom chat with the team at Roche to have a frank, candid discussion about the recent halting of GENERATION-HD1, the Phase 3 clinical trial that was testing the ability of the antisense ... Read more

Another tool in the box: Creation of a molecular “dimmer switch” advances gene editing

Published date: 30 August, 2021

A team of scientists recently created an innovative genetic system where a drug taken by mouth could be used to control the action of a gene editor, like those used in CRISPR systems. This has useful applications for research studies in cells and animals, and perhaps most importantly, could lead to improvements in the safety ... Read more

Unpacking recent gene therapy press

Published date: 16 August, 2021

A recent announcement from Voyager Therapeutics outlined a shift in the company’s strategy towards an exciting new technology for gene therapy delivery. Unfortunately this also means that in the short term, they have dropped previous plans to test an HD gene therapy in people with HD. While this news is disappointing, the decision to embrace ... Read more

Does blood hold the key to testing treatments earlier in HD patients?

Published date: 4 August, 2021

Researchers at Johns Hopkins led by Wenzhen Duan have developed a non-invasive way to track progression of Huntington’s disease (HD) which could be used before patients even start showing symptoms. Using a type of brain scan called an MRI, the researchers have shown that in mouse models of HD they can accurately measure the amount ... Read more

A first for CRISPR gene editing could have wider applications for human disease

Published date: 21 July, 2021

A recent clinical trial successfully tested the safety of CRISPR gene editing to reduce the amount of a toxic protein in patients with Familial Transthyretic (TTR) Amyloidosis. Although this study is unrelated to Huntington’s disease, it’s a first for gene editing, and the results could have implications for HD and other brain disorders. CRISPR-Cas9 Clustered ... Read more